Based on Clemson University research, 3D cancer cell modelling spinout Kiyatec has increased its total financing to $14.9m with the help of clinical lab operator LabCorp and VC firm VentureSouth.

Kiyatec, a US-based cancer cytology modelling spinout of Clemson University, obtained an initial $3m in series B2 funding on Wednesday led by VC firm VentureSouth and backed by clinical laboratory operator LabCorp.
Founded in 2005, Kiyatec has developed a technology called 3D-Predict that provides ex vivo predictive modelling of live cancer cells in 3D cell culture environments.
Kiyatec’s platform helps inform patient-specific clinical decisions when prescribing cancer therapies and also supports the development of new drugs.
The…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?